The Medicines Company and Daiichi Sankyo, Inc. Announce Angiox(R) (Bivalirudin) Co-Promotion for Germany

PARSIPPANY, NJ--(Marketwire - October 28, 2011) - The Medicines Company (Deutschland) GmbH (NASDAQ: MDCO) and Daiichi Sankyo Deutschland GmbH today announced a co-promotion for Angiox® (bivalirudin) in Germany, beginning on November 1, 2011.

Angiox is The Medicines Company's injectable direct thrombin inhibitor indicated in Europe as an anticoagulant for adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-elevation MI (STEMI) undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation MI (NSTEMI) planned for urgent or early intervention. The product carries a Class 1B recommendation from the European Society of Cardiology in both Germany and Europe for use in patients with STEMI and NSTEMI undergoing PCI.

The companies estimate that the partnership will enable 100% combined service coverage for hospitals in Germany that provide interventional cardiology services and manage acute coronary syndromes -- the key indication areas for Angiox.

Wolfgang Hecht, leader of The Medicines Company team in Germany, commented, "This co-promotion is an important way for The Medicines Company to strengthen its presence in Germany and Europe. Germany is Europe's largest acute cardiovascular market and has leading cardiology science and sophisticated economic demands. We expect that combining the studies of Angiox in German cardiology centers with Daiichi Sankyo's established presence in acute care cardiology will accelerate patient access to PCI treatment with Angiox."

Ralf Göddertz, Managing Director of Daiichi Sankyo Germany, commented, "With Angiox, we achieve an even stronger position in cardiology and have the opportunity to expand our reputation as a competent partner for hospitals and cardiologists."

Oliver Appelhans, Manager Country Operations of Daiichi Sankyo Deutschland GmbH, added: "This partnership with The Medicines Company potentially generates added value for German patients with acute coronary syndromes. Angiox is an excellent addition to our therapeutic offerings. Furthermore, our customers now have the opportunity to benefit from the combined support of both companies."

About The Medicines Company

The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.

About Angiox® (bivalirudin)

In Europe, Angiox currently is indicated as an anticoagulant for adult patients undergoing PCI, including patients with STEMI undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation MI planned for urgent or early intervention. Please see full prescribing information available at http://www.angiox.com.

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates," "plans" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether physicians, patients and other key decision-makers will accept clinical trial results, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approvals, whether physicians, patients and other key decision-makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on August 2, 2011, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.